Mesothelioma: A Review

Ochsner Journal

Volumn 12, Issue 1, 2012, Pages 70-79

  Mott, Frank E ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Asbestos; Diagnosis; Malignant pleural mesothelioma; Targeted therapies; Treatment

Indexed keywords

ASBESTOS; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOXORUBICIN; ERLOTINIB; FOLINIC ACID; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; METHOTREXATE; MITOMYCIN; NAVELBINE; PAZOPANIB; PEMETREXED; PLACEBO; RANPIRNASE; SORAFENIB; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; VATALANIB; VINBLASTINE; VORINOSTAT;

CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG RESECTION; MESOTHELIOMA; NEPHROTOXICITY; OCCUPATIONAL EXPOSURE; PATHOGENESIS; PHOTODYNAMIC THERAPY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURECTOMY; POSITRON EMISSION TOMOGRAPHY; REVIEW; UNSPECIFIED SIDE EFFECT; WORKPLACE;

EID: 84858663671     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev. 2008 Nov;17(6):525-534
2. Surveillance, Epidemiology, and End Results Cancer Statistics Review-Mesothelioma fast stats. http://seer.cancer.gov/faststats/selections.php?series5cancer. Accessed May 27, 2011.
3. Louisiana Tumor Registry Data, 2009. http://publichealth.lsuhsc.edu/tumorregistry. Accessed March 27, 2011.
4. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 1980 Dec 15;46(12):2736-2740
5. Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010 Feb;42(2):133-139
6. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006 Jul 1;107(1):108-115
7. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005 Sep 21;97(18):1354-1365
8. Deutsch M, Land SR, Begovic M, Cecchini R, Wolmark N. An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma. Am J Clin Oncol. 2007 Jun;30(3):294-296
9. Takagi A, Hirose A, Nishimura T, et al. Induction of mesothelioma in p53+/2 mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci. 2008 Feb;33(1):105-116
10. Poland CA, Duffin R, Kinloch I, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol. 2008 Jul;3(7):423-428. Epub 2008 May 20.
11. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003 Jul;126(1): 11-16
12. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006 Apr;19(4): 514-523
13. Husain AN, Colby TV, Ordo ́ n ̃ ez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009 Aug;133(8):1317-1331
14. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008 Feb;83(2):235-250. Erratum in: Mayo Clin Proc. 2009 Sep;84(9):847.
15. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer. 1993 Jul 15;72(2):394-404
16. Edge S, Byrd DR, Compton CC, Fritz AG, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Publications; 2010.
17. Arapis K, Caliandro R, Stern JB, Girard P, Debrosse D, Gossot D. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. Surg Endosc. 2006 Jun;20(6):919-923. Epub 2006 May 2.
18. Aelony Y, Yao JF. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series. Respirology. 2005 Nov;10(5):649-655
19. Schulze M, Boehle AS, Kurdow R, Dohrmann P, Henne-Bruns D. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg. 2001 Jun;71(6):1809-1812
20. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-65
21. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996 Apr;111(4):815-825; discussion 825-826
22. Buduhan G, Menon S, Aye R, Louie B, Mehta V, Vallières E. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2009 Sep;88(3):870-875; discussion 876.
23. Trousse DS, Avaro JP, D'Journo XB, et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg. 2009 Oct;36(4):759-763. Epub 2009 Jun 11.
24. Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg. 2009 Sep;138(3): 619-624. Epub 2009 Mar 9.
25. Taub RN, Antman KH. Chemotherapy for malignant mesothelioma. Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):361-366
26. Rudd RM. Malignant mesothelioma. Br Med Bull. 2010;93: 105-123. Epub 2010 Jan 4.
27. Treasure T, Waller D, Tan C, et al. The Mesothelioma and Radical Surgery randomized controlled trial: the MARS feasibility study. J Thorac Oncol. 2009 Oct;4(10):1254-1258
28. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007 Oct;2(10):957-965
29. Teh E, Fiorentino F, Tan C, Treasure T. A systematic review of lungsparing extirpative surgery for pleural mesothelioma. J R Soc Med. 2011 Feb;104(2):69-80
30. Friedberg JS. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):177-187
31. Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol). 1991 Nov;3(6):315-317
32. Ahamad A, Stevens CW, Smythe WR, et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):768-775
33. Su S. Mesothelioma: path to multimodality treatment. Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):125-131
34. Muers MF, Stephens RJ, Fisher P, et al; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-1694
35. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009 Jan;63(1):94-97. Epub 2008 May 16.
36. Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer. 2008 Jul 8;99(1):44-50. Epub 2008 Jun 10.
37. Bischoff HG, Manegold C, Knopp M, Blatter J, Drings P. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol. 1998;17(Abstract 1784):A464.
38. Kindler HL, Millard F, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001 Feb-Mar;31(2-3):311-317
39. van Meerbeeck JP, Baas P, Debruyne C, et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 1999 Jun 15;85(12): 2577-2582
40. Jackman DM. Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):154-158
41. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002 Nov;38(2):111-121
42. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-2644
43. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer. 1992 Jun;65(6):956-960
44. Li Q, Ding L, Yu JJ, et al. Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. Int J Oncol. 1998 Nov;13(5):987-992
45. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005 Mar;127(3):978-983
46. Zucali PA, Giovannetti E, Destro A, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/ carboplatin. Clin Cancer Res. 2011 Apr 15;17(8):2581-2590. Epub 2011 Jan 24.
47. Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 2010 Mar 20;28(9):1534-1539. Epub 2010 Feb 22.
48. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-1704
49. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-2342
50. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-2550. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.
51. König J, Tolnay E, Wiethege T, Müller K. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration. 2000;67(1):36-40
52. König JE, Tolnay E, Wiethege T, Müller KM. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch. 1999 Jul;435(1):8-12
53. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001 Apr;193(4):468-475
54. Karrison T, Kindler HL, Gadara R, et al. Final analysis of a multi-center, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol. 2007 Jun 20;25(Suppl 18S Abstract 7526):391s.
55. Jahan TM, Gu L, Wang X, et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol. 2006 Jun 20(Suppl 18S Abstract 7081):364s.
56. Janne PA, Wang XF, Krug LM, Hodgson L, Vokes EE, Kindler HL. Sorafenib in malignant mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol. 2007 Jun 20(Suppl 18S Abstract 7707):45s.
57. Nowak AK, Millward MJ, Francis R, van der Schaaf A, Musk AW, Byrne MJ. Phase II study of Sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol. 2008 May 20;26(Suppl-Abstract 8063):439s.
58. Govindan R, Riter J, Suppiah R. EGFR and HER-2 overexpression in malignant mesothelioma. Proc Am Soc Clin Oncol. 2001;20(Abstract 3106).
59. Jänne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15;62(18):5242-5247
60. Govindan R, Kratzke RA, Herndon JE 2nd, et al. Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005 Mar 15;11(6):2300-2304
61. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007 Jun 10;25(17):2406-2413
62. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15;113(4):808-814
63. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006 Jan;7(4):257-261
64. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol. 2002 Jan 1;20(1):274-281
65. Vogelzang N, Taub R, Shin D, et al. Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): Analysis of survival. Proc Am Soc Clin Oncol. 2000;19(Abstract 2274):A577.
66. Delage B, Fennell DA, Nicholson L, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010 Jun 15;126(12):2762-2772
67. Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs. 2006 Jul;15(7):815-822
68. Gregorc V, Zucali PA, Santoro A, et al. Phase II study of asparagineglycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol. 2010 May 20;28(15):2604-2611. Epub 2010 Apr 20.